Generics controversy issue widens

Jun 05, 2006

A dispute between the U.S. Justice Department and Federal Trade Commission over generic drugs is reportedly widening with implications for the drug firms.

The issue relates to the legality of deals between drug companies and those making the generic versions, reports the Financial Times. As the controversy heats up, the FTC, over the objections of the Bush administration, may file a second petition urging the Supreme Court to decide the issue.

The Financial Times report says the rift between the two departments results from a complex patent dispute involving a company and a drug for treating the side effects of blood pressure medicines. The FTC claims a deal the company and a generic rival made subsequently is anti-competitive.

The report says while settlements between drug companies do not usually violate antitrust laws, they do when branded drug groups offer their generic rivals deals to stay out of the market until a certain date.

Copyright 2006 by United Press International

Explore further: Heat blamed for spray vaccine's failure against swine flu

add to favorites email to friend print save as pdf

Related Stories

Body by smartphone

Jul 30, 2014

We love our smartphones. Since they marched out of the corporate world and into the hands of consumers about 10 years ago, we've relied more and more on our iPhone and Android devices to organize our schedules, ...

Merck 2Q profit more than doubles

Jul 29, 2014

A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double its second-quarter profit, raise the lower end of its profit forecast and easily top analysts' expectations.

X-ray imaging reveals a complex core

Jul 04, 2014

Macromolecular complexes composed of self-assembling proteins and nucleic acids hold promise for a wide range of applications, including drug delivery, sensing and molecular electronics. Scientists have developed ...

Recommended for you

Suicide rates rising for older US adults

25 minutes ago

Suicide rates for adults between 40 and 64 years of age in the U.S. have risen about 40% since 1999, with a sharp rise since 2007. One possible explanation could be the detrimental effects of the economic downturn of 2007-2009, ...

Experts warn of stem cell underuse

35 minutes ago

Since the first experimental bone marrow transplant over 50 years ago, more than one million hematopoietic stem cell transplantations (HSCT) have been performed in 75 countries, according to new research charting the remarkable ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.